| Disease | A RANDOMIZED, PLACEBO-CONTROLLED TRIAL INVOLVING 30 PATIENTS TO DETERMINE THE EFFECTS OF AN EPHEDRINE AND SYNEPHRINE-BASED COMPOUND ON BODY MASS, BODY COMPOSITION, METABOLIC VARIABLE, AND MOOD STATES IN HEALTHY OVERWEIGHT ADULTS. THIRTY SUBJECTS
WITH A BODY MASS INDEX > 27 KG/M2 WERE ASSIGNED RANDOMLY TO THE EXPERIMENTAL GROUP OR THE PLACEBO GROUP. THE EXPERIMENTAL GROUP RECEIVED A CAPSULE CONTAINING EPHEDRINE ALKALOIDS 20 MG, SYNEPHRINE 5 MG, CAFFEINE 200 MG, AND SALICIN 20 MG
TWICE DAILY FOR 8 WEEKS, WHEREAS THE OTHER GROUP RECEIVED A MATCHING PLACEBO. IN ADDITION, ALL PATIENTS PERFORMED A CROSS-TRAINING EXERCISE PROGRAM 3 DAYS PER WEEK UNDER THE GUIDANCE OF AN EXERCISE PHYSIOLOGIST. DURING THE EXERCISE SESSIONS,
PATIENTS ACHIEVED 70% OF AGE-PREDICTED MAXIMUM HEART RATE. THE EXPERIMENTAL GROUP HAD A SIGNIFICANTLY GREATER WEIGHT LOSS COMPARED WITH THE PLACEBO GROUP (3.14 KG VS 2.05 KG, RESPECTIVELY; P < 0.05). THE EXPERIMENTAL GROUP EXPERIENCED A 16%
DECREASE IN BODY FAT COMPARED WITH A 1% INCREASE FOR THE PLACEBO GROUP. THE BETWEEN-GROUP DIFFERENCE WAS SIGNIFICANT (P = 0.005). BOTH GROUPS ACHIVED A SIGNIFICANT REDUCTION IN FAT-FREE MASS; HOWEVER, THE REDUCTION IN THE PLACEBO GROUP WAS
GREATER THAN THAT OF THE EXPERIMENTAL GROUP. THIS SUGGESTS A MUSCLE-SPARING EFFECT IN THE EXPERIMENTAL GROUP. NO SIGNIFICANT CHANGES IN BLOOD PRESSURE, SERIAL ELECTROCARDIOGRAMS, PULSE RATE, SERUM CHEMISTRY, OR CALORIC INTAKE WERE NOTED. THESE
FINDINGS INDICATE THE APPARENT SAFETY AND EFFICACY OF THE EPHEDRINE- AND SYNEPHRINE-BASED COMPOUND WITHIN THE CONFINES OF THIS STUDY. |